Samuel Stone
Internal Medicine · Boston, MANPI 1750944971
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,714 and has fallen 61.9% since, to $654 in 2025. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$900
- Amgen$640
- Pfizer$558
- Alnylam Pharmaceuticals Inc.$535
- Johnson & Johnson$355
- Abiomed$340
- plus $2K from 18 others
Across 1 payment — averaging $143.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$143
What the payments were for
- Food & beverage$4,87198%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $900 |
| Amgen | 21 | $640 |
| Pfizer | 20 | $558 |
| Alnylam Pharmaceuticals Inc. | 28 | $535 |
| Johnson & Johnson | 6 | $355 |
| Abiomed | 7 | $340 |
| Daiichi Sankyo Inc. | 12 | $318 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $265 |
| Regeneron Healthcare Solutions, Inc. | 2 | $161 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $157 |
| Heartflow, Inc. | 2 | $132 |
| Boehringer Ingelheim | 4 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $87 |
| Merck | 5 | $85 |
| Novartis | 3 | $72 |
| Bayer | 3 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $44 |
| Abbott | 1 | $32 |
| Novo Nordisk | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,954 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 46 | $80,305 |
| JardianceEmpagliflozin | 48 | $64,947 |
| EliquisApixaban | 40 | $57,681 |
| FarxigaDapagliflozin Propanediol | 30 | $48,466 |
| Repatha SureclickEvolocumab | 14 | $9,120 |
| Metoprolol Succinate | 81 | $1,859 |
| Atorvastatin Calcium | 102 | $1,602 |
| Rosuvastatin Calcium | 39 | $962 |
| Ezetimibe | 29 | $745 |
| Losartan Potassium | 27 | $427 |
| Lisinopril | 35 | $283 |
| Torsemide | 13 | $262 |
| Flecainide Acetate | 12 | $242 |
| Amlodipine Besylate | 36 | $242 |
| Carvedilol | 22 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $72 | $80,30546 claims |
| Boehringer IngelheimJardiance | $105 | $64,94748 claims |
| PfizerEliquis | $558 | $57,68140 claims |
| AstraZenecaFarxiga | $900 | $48,46630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.